ASCO approaches an important milestone with the first CancerLinQ prototype
What if there was a place where cancer care teams could go to learn, in real time, how to make the best treatment decision for their patients? Where doctors in Michigan could learn if a new cancer treatment is proving effective for patients all across the country, or if younger women are responding better to a certain therapy than older women?
Really, the most exciting and important opportunity here is this: what if there were a way to learn not only from the three percent of patients who participate in clinical trials, but the other 97 percent as well, and then share this knowledge with healthcare providers across the country, and to use what we’ve learned to set new treatment standards and guidelines?
This is a reality that the American Society of Clinical Oncology (ASCO) and Conquer Cancer Foundation (CCF) are working toward with a ground-breaking, new rapid-learning system (RLS) for oncology care named CancerLinQ.
Recently, ASCO shared that this innovative project is approaching an important milestone – the completion of the first CancerLinQ prototype, filled with records from over 130,000 breast cancer patients and made possible in part by a $1 million grant from Susan G. Komen for the Cure. This means that once the final version of the CancerLinQ system is complete, regardless of the electronic health record source, delays in paperwork processing and/or any other obstacles, breast cancer care providers nationwide will be able to explore de-identified data from patients across the country, allowing them to make faster, better-informed decisions for their patients.
We still have a lot to learn about breast cancer, and Komen’s global research portfolio is looking for answers to some of the toughest questions regarding breast cancer prevention, early detection, triple negative breast cancer, metastasis and much more. But for now, it’s absolutely critical that we take what we already DO know about breast cancer treatment and care and make it accessible to patients and care providers everywhere. CancerLinQ provides us with a unique opportunity to share information that we have never been able to share before, ensuring that where a woman lives does not determine whether she lives and bringing us one step closer to a world without breast cancer.
ASCO announced the completion of the prototype this morning, March 27, at a stakeholder event. To view the event, please go to www.asco.org/bigdatawebcast.
About the author
As Chief Mission Officer at Susan G. Komen®, Chandini Portteus provides strategic leadership and management of Komen's key mission areas: research, community health, public policy and global programs. Her oversight includes an active research portfolio of more than $300 million in funding worldwide and community health outreach that serves millions of women and families annually through funding of education, screening, psychosocial and medical services to 2,000 Komen grantees.